{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:55:23Z","timestamp":1760644523101},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,10]]},"DOI":"10.1093\/jac\/44.4.477","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:24:55Z","timestamp":1027722295000},"page":"477-481","source":"Crossref","is-referenced-by-count":5,"title":["Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniaein a murine sepsis model"],"prefix":"10.1093","volume":"44","author":[{"given":"Melinda K.","family":"Lacy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Anne","family":"Banevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles H.","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Quintiliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1999,10]]},"reference":[{"key":"key\n\t\t\t\t20170411034530_R1","doi-asserted-by":"crossref","unstructured":"Bartlett, J. G. & Mundy, L. M. (1995). Community-acquired pneumonia. New England Journal of Medicine333, 1618\u201324.","DOI":"10.1056\/NEJM199512143332408"},{"key":"key\n\t\t\t\t20170411034530_R2","doi-asserted-by":"crossref","unstructured":"Fine, M. J., Smith, M. A., Carson, C. A., Mutha, S. S., Sankey, S. S., Weissfeld, L. A. et al. (1996). Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. Journal of the American Medical Association275, 134\u201341.","DOI":"10.1001\/jama.1996.03530260048030"},{"key":"key\n\t\t\t\t20170411034530_R3","doi-asserted-by":"crossref","unstructured":"Gwaltney, J. M. (1996). Acute community-acquired sinusitis. Clinical Infectious Diseases23, 1209\u201323.","DOI":"10.1093\/clinids\/23.6.1209"},{"key":"key\n\t\t\t\t20170411034530_R4","doi-asserted-by":"crossref","unstructured":"Schuchat A., Robinson, K., Wenger, J. D., Harrison, L. H., Farley, M., Reingold A. L. et al. (1997). Bacterial meningitis in the United States in 1995. New England Journal of Medicine337, 970\u20136.","DOI":"10.1056\/NEJM199710023371404"},{"key":"key\n\t\t\t\t20170411034530_R5","doi-asserted-by":"crossref","unstructured":"Doern, G. V., Brueggemann, A., Holley, H. P. & Rauch, A. (1996). Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994\u20131995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy40, 1208\u201313.","DOI":"10.1128\/AAC.40.5.1208"},{"key":"key\n\t\t\t\t20170411034530_R6","doi-asserted-by":"crossref","unstructured":"Goldstein, F. W. & Acar, J. F. (1996). Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992\u201393 Western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. Journal of Antimicrobial Chemotherapy38, Suppl. A, 71\u201384.","DOI":"10.1093\/jac\/38.suppl_A.71"},{"key":"key\n\t\t\t\t20170411034530_R7","doi-asserted-by":"crossref","unstructured":"Simberkoff, M. S. (1994). Drug-resistant pneumococcal infections in the United States. A problem for clinicians, laboratories, and public health. Journal of the American Medical Association271, 1875\u20136.","DOI":"10.1001\/jama.1994.03510470079039"},{"key":"key\n\t\t\t\t20170411034530_R8","doi-asserted-by":"crossref","unstructured":"Thornsberry, C., Ogilvie, P., Kahn, J. & Mauriz, Y. (1997). Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996\u20131997 respiratory season. The Laboratory Investigator Group. Diagnostic Microbiology and Infectious Diseases29, 249\u201357.","DOI":"10.1016\/S0732-8893(97)00195-8"},{"key":"key\n\t\t\t\t20170411034530_R9","doi-asserted-by":"crossref","unstructured":"Schreiber, J. R. & Jacobs, M. R. (1995). Antibiotic-resistant pneumococci. Pediatric Clinics of North America42, 519\u201337.","DOI":"10.1016\/S0031-3955(16)38977-5"},{"key":"key\n\t\t\t\t20170411034530_R10","doi-asserted-by":"crossref","unstructured":"Brighty, K. E. & Gootz, T. D. (1997). The chemistry and biological profile of trovafloxacin. Journal of Antimicrobial Chemotherapy39 Suppl. B, 1\u201314.","DOI":"10.1093\/jac\/39.suppl_2.1"},{"key":"key\n\t\t\t\t20170411034530_R11","doi-asserted-by":"crossref","unstructured":"Gootz, T. D., Zaniewski, R., Haskell, S., Schmieder, B., Tankovic, J., Girard, D. et al. (1996). Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrobial Agents and Chemotherapy40, 2691\u20137.","DOI":"10.1128\/AAC.40.12.2691"},{"key":"key\n\t\t\t\t20170411034530_R12","doi-asserted-by":"crossref","unstructured":"Klugman, K. & Wasas, A. (1995). In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae.Journal of Antimicrobial Chemotherapy36, 873\u20134.","DOI":"10.1093\/jac\/36.5.873"},{"key":"key\n\t\t\t\t20170411034530_R13","unstructured":"National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically\u2014Fourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA."},{"key":"key\n\t\t\t\t20170411034530_R14","doi-asserted-by":"crossref","unstructured":"Fantin, B., Leggett, J., Ebert, S. & Craig, W. A. (1991). Correlation between in vitro and in vivo activity of antimicrobial agents against Gram-negative bacilli in a murine infection model. Antimicrobial Agents and Chemotherapy35, 1413\u201322.","DOI":"10.1128\/AAC.35.7.1413"},{"key":"key\n\t\t\t\t20170411034530_R15","doi-asserted-by":"crossref","unstructured":"Sullivan, M. C., Cooper, B. W., Nightingale, C. H., Quintiliani, R. & Lawlor, M. T. (1993). Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrobial Agents and Chemotherapy37, 234\u20139.","DOI":"10.1128\/AAC.37.2.234"},{"key":"key\n\t\t\t\t20170411034530_R16","doi-asserted-by":"crossref","unstructured":"Nau, R., Schmidt, T., Kaye, K., Froula, J. F. & Tauber, M. G. (1995). Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrobial Agents and Chemotherapy39, 593\u20137.","DOI":"10.1128\/AAC.39.3.593"},{"key":"key\n\t\t\t\t20170411034530_R17","doi-asserted-by":"crossref","unstructured":"Paris, M. M., Hickey, S. M., Trujillo, M., Shelton, S. & McCracken, G. H. (1995). Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy39, 1243\u20136.","DOI":"10.1128\/AAC.39.6.1243"},{"key":"key\n\t\t\t\t20170411034530_R18","doi-asserted-by":"crossref","unstructured":"Girard, A. E., Girard, D., Gootz, T. D., Faiella, J. A. & Cimochowski, C. R. (1995). In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.Antimicrobial Agents and Chemotherapy39, 2210\u201316.","DOI":"10.1128\/AAC.39.10.2210"},{"key":"key\n\t\t\t\t20170411034530_R19","unstructured":"Azoulay-Dupuis, E., Bedos, J. P., Bauchet, J., Reux, V., Muffat-Joly, M. & Carbon, C. (1996). Efficacy of trovafloxacin against penicillin-susceptible and resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract B43, p. 29. American Society for Microbiology, Washington, DC."},{"key":"key\n\t\t\t\t20170411034530_R20","unstructured":"Lacy, M. K., Nicolau, D. P., Banevicius, M. A., Nightingale, C. H. & Quintiliani, R. (1997). Protective effect of trovafloxacin, ciprofloxacin, and ampicillin against isolates of S. pneumoniae with varying penicillin susceptibilities. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Abstract B97, p. 44. American Society for Microbiology, Washington, DC."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/44\/4\/477\/13057235\/JAC444477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T08:24:12Z","timestamp":1583310252000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/44.4.477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[1999,10]]},"published-print":{"date-parts":[[1999,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/44.4.477","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[1999,10]]}}}